Indonesia vs Kenya: Hepatitis B surface antigen (HBsAg) prevalence
Indonesia
0.7%
in 2024
Kenya
0.7%
in 2024
Indonesia rank
43rd
Kenya rank
43rd
Hepatitis B surface antigen (HBsAg) prevalence over time
- Indonesia
- Kenya
How they compare
Indonesia currently reports 0.7% against 0.7% in Kenya, a difference of 0.0%.
Across all 10 years both countries report, Kenya has been ahead every year.
Indonesia ranks 43rd and Kenya ranks 43rd of 194 countries.
Kenya has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Indonesia | Kenya | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.9% | 1.1% | 0.2% | Kenya |
| 2020s | 0.8% | 0.9% | 0.0% | Kenya |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Indonesia or Kenya?
- Indonesia, at 0.7% against 0.7% in Kenya as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Indonesia and Kenya?
- 0.0%, with Indonesia ahead.
- How many years of comparable data are there for Indonesia and Kenya?
- 10 years are reported by both, from 2015 to 2024.
- How do Indonesia and Kenya rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Indonesia ranks 43rd and Kenya ranks 43rd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.